The multiple sclerosis study published in the journal The Lancet found that alemtuzumab significantly reduced the number of attacks or relapses by people with MS.
This result was seen both in patients who had not previously received any treatment and those who have continued to show disease activity while taking an existing treatment for MS.
In one trial with patients who had recently relapsed, new episodes were reduced by 49% more than that achieved by the current standard treatment.
Over a two-year period, 65% of patients on alemtuzumab compared with 47% of patients on interferon did not relapse.
More top news
Vacuum cleaner manufacturer Dyson has said that it will invest £2 billion in electric car development.
Victims have won a ruling allowing them to launch a High Court group action seeking damages over contaminated blood products.
Jaffa Cake fans have been left outraged after boxes of the biscuits dropped in size from 12 to 10.